European Commission approves first medicine for prurigo nodularis

Dupixent®, the first and only targeted medicine for prurigo nodularis (PN) has been approved by the EC for adults with moderate-to-severe PN.

Related Keywords

Georged Yancopoulos ,Naimish Patel ,European Union ,European Commission ,Head Of Global Development ,Committee For Medicinal Products Human Use ,Global Development ,Worst Itch Numeric Rating Scale ,Global Assessment ,Dermatology Life Quality Index ,Numerical Rating Scale ,Hospital Anxiety ,Depression Scale ,Medicinal Products ,Human Use ,Chief Scientific Officer ,